Table 3.
Comparison of different scoring tools, which are used in screening patients with anaphylaxis to evaluate the risk of underlying clonal mast cell disease (adapted from references: [82,95,96]).
| REMA Score | Karolinska Score | NICAS | ||||
|---|---|---|---|---|---|---|
| VARIABLES | Yes | No | Yes | No | Yes | No |
| Male gender | +1 | −1 | +1 | −1 | +1 | −1 |
| Clinical symptoms | ||||||
| Angioedema | n/a | n/a | n/a | n/a | n/a | +1 |
| Urticaria | n/a | n/a | n/a | n/a | +1 | n/a |
| Flushing | n/a | n/a | n/a | n/a | −1 | n/a |
| Urticaria/Pruritus/Angioedema | −2 | +1 | −2 | +1 | n/a | n/a |
| Syncope | +3 | 0 | +3 | 0 | +3 | 0 |
| Baseline tryptase | ||||||
| ≤11.4 ng/mL | n/a | n/a | −1 | n/a | −1 | n/a |
| >11.4 ng/mL | n/a | n/a | n/a | n/a | +1 | n/a |
| >20 ng/mL | n/a | n/a | +2 | n/a | n/a | n/a |
| <15 ng/mL | −1 | n/a | n/a | n/a | n/a | n/a |
| >25 ng/mL | +2 | n/a | n/a | n/a | n/a | n/a |
| KIT D816V mutation | n/a | n/a | n/a | n/a | +3 | −1 |
| Positive score * | ≥2 points | ≥2 points | ≥2 points | |||
| Outcome | High risk | High risk | High risk | |||
Abbreviations: REMA, the Spanish Network for Mastocytosis (REMA); NICAS, National Institute of Health Idiopathic Clonal Anaphylaxis Score; n/a, non-applicable; * The sum of positive and negative points of ≥ 2 is considered to be positive and indicates a high probability for underlying clonal mast cell disorders.